Clinical trial NCT02431403 - References

Lymphoma, Non-Hodgkin — ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma

Citation(s)

•   Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L
  Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia. 2004 Mar;18(3):409-14.
•   Andrae J, Gallini R, Betsholtz C
  Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008 May 15;22(10):1276-312. doi: 10.1101/gad.1653708. Review.
•   Aozasa K, Zaki MA
  Epidemiology and pathogenesis of nasal NK/T-cell lymphoma: a mini-review. ScientificWorldJournal. 2011 Feb 14;11:422-8. doi: 10.1100/tsw.2011.41. Review.
•   Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, Martínez J, López J, Suárez JG, Moreno MJ, Merino MA, Gutiérrez NC, Hernández-Rivas JM
  Response to imatinib mesylate in patients with hypereosinophilic syndrome. Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.
•   Brauns TC, Schultewolter T, Dissemond J, Maschke J, Goos M
  C-KIT expression in primary cutaneous T-cell lymphomas. J Cutan Pathol. 2004 Oct;31(9):577-82.
•   Capdeville R, Buchdunger E, Zimmermann J, Matter A
  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002 Jul;1(7):493-502. Review.
•   Chen YP, Chang KC, Su WC, Chen TY
  The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas. Ann Hematol. 2008 Dec;87(12):985-90. doi: 10.1007/s00277-008-0539-z. Epub 2008 Jul 17.
•   Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma
  Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.
•   Choe YS, Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Do YR, Kwon KY, Song HS, Lee MH, Park TI
  c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas. Leuk Lymphoma. 2006 Feb;47(2):267-70.
•   Edling CE, Hallberg B
  c-Kit--a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39(11):1995-8. Epub 2007 Jan 20. Review.
•   Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF
  Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma. 1998 Aug;30(5-6):459-66. Review.
•   Giantin M, Aresu L, Aricò A, Gelain ME, Riondato F, Comazzi S, Dacasto M
  Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: might c-kit represent a therapeutic target? Vet Immunol Immunopathol. 2013 Aug 15;154(3-4):153-9. doi: 10.1016/j.vetimm.2013.05.014. Epub 2013 May 30.
•   Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH
  Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000 Nov 1;18(21):3633-42.
•   Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L
  A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol. 2011 Sep;68(3):643-51. doi: 10.1007/s00280-010-1530-7. Epub 2010 Dec 1.
•   Hollmann CA, Tzankov A, Martínez-Marignac VL, Baker K, Grygorczyk C, Grygorczyk R, Foulkes W, Nadeau J, Dirnhofer S, Aloyz R
  Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leuk Res. 2010 May;34(5):585-93. doi: 10.1016/j.leukres.2009.08.030. Epub 2009 Sep 16.
•   Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K, Nomura T
  Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 2000 May 1;60(9):2345-7.
•   Huang Y, de Reyniès A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, Bosq J, Brière J, Petit B, Thomas E, Coppo P, Marafioti T, Emile JF, Delfau-Larue MH, Schmitt C, Gaulard P
  Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010 Feb 11;115(6):1226-37. doi: 10.1182/blood-2009-05-221275. Epub 2009 Nov 30.
•   Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD
  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991 Dec 1;78(11):2962-8.
•   Melnyk A, Rodriguez A, Pugh WC, Cabannillas F
  Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997 Jun 15;89(12):4514-20.
•   Passam FH, Alexandrakis MG, Kafousi M, Fotinou M, Darivianaki K, Tsirakis G, Roussou PA, Stathopoulos EN, Siafakas NM
  Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract. 2009;205(1):11-20. doi: 10.1016/j.prp.2008.07.007. Epub 2008 Oct 23.
•   Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, Went P, Klein U, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA
  Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007 Mar;117(3):823-34. Epub 2007 Feb 15.
•   Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A
  Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood. 1994 Feb 1;83(3):785-92.
•   Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A
  Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005 May 15;105(10):4051-9. Epub 2005 Jan 27.
•   Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W
  A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul;6(6):609-11.
•   Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA
  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013 Jun 27;121(26):5192-202. doi: 10.1182/blood-2013-03-490763. Epub 2013 Apr 30.
•   Shimizu H, Popova M, Fleury F, Kobayashi M, Hayashi N, Sakane I, Kurumizaka H, Venkitaraman AR, Takahashi M, Yamamoto K
  c-ABL tyrosine kinase stabilizes RAD51 chromatin association. Biochem Biophys Res Commun. 2009 May 1;382(2):286-91. doi: 10.1016/j.bbrc.2009.03.020. Epub 2009 Mar 11.
•   Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al
  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22.
•   Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F
  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun;12(6):1169-76.
•   Zhu Y, Qian SX
  Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients. Onco Targets Ther. 2014 Mar 6;7:395-404. doi: 10.2147/OTT.S38846. eCollection 2014. Review.

Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma

Details for clinical trial NCT02431403